Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer
about
A Perspective of Immunotherapy for Prostate CancerTasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospectsSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine modelsThe anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growthIdentification of small molecule inhibitors for influenza a virus using in silico and in vitro approaches.The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer.Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies.Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients.Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer.Applying dried blood spot sampling with LCMS quantification in the clinical development phase of tasquinimod.A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.Neutrophils and the S100A9 protein critically regulate granuloma formation
P2860
Q26741277-46BC2A00-F600-47EF-90C9-44EB2FD00692Q26770428-858A221D-DC83-4607-90E9-02276D325DCBQ26852544-A844300A-1742-4643-B1B8-B78B3E129927Q35071167-BBF46475-1FDA-4295-BD52-1E3429591834Q36072831-BDE5A4E6-CD40-4071-9139-2ABF0DB7D80BQ36300881-80AED447-97CD-4CB2-8DF5-FE20303ACAD4Q38223389-25EB1E3E-8432-4E7B-B538-6327685F38ECQ38487988-5567238F-640E-4F8C-9915-7FA08A22D6D9Q38959297-798664D6-DB06-42A5-BE2F-9A36EDB6FE73Q38974777-4EA553C6-70B9-402B-AE70-D68FD8EFD410Q40468733-CC69A78A-1080-4005-85B0-4784A69B4F88Q41550939-4C9F77E2-C229-4C1E-AAF2-CD0399239DE3Q41573500-75221742-89B0-4632-AD63-CC6767C2945FQ41584077-CE399875-38FD-41A8-AC1D-A8D0926159BAQ50068855-93AC6614-C017-4994-BC4C-949CA8C49D89Q57096408-F627738D-4FE1-4A9A-8DE1-AACC9DA6271C
P2860
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Long-term survival and biomark ...... tion-resistant prostate cancer
@ast
Long-term survival and biomark ...... tion-resistant prostate cancer
@en
Long-term survival and biomark ...... tion-resistant prostate cancer
@nl
type
label
Long-term survival and biomark ...... tion-resistant prostate cancer
@ast
Long-term survival and biomark ...... tion-resistant prostate cancer
@en
Long-term survival and biomark ...... tion-resistant prostate cancer
@nl
prefLabel
Long-term survival and biomark ...... tion-resistant prostate cancer
@ast
Long-term survival and biomark ...... tion-resistant prostate cancer
@en
Long-term survival and biomark ...... tion-resistant prostate cancer
@nl
P2093
P2860
P1476
Long-term survival and biomark ...... tion-resistant prostate cancer
@en
P2093
A J Armstrong
G Forsberg
J E Damber
J Polikoff
J R Gingrich
M A Carducci
P2860
P304
P356
10.1158/1078-0432.CCR-13-1581
P407
P577
2013-11-19T00:00:00Z